US needs suspension option for risk-benefit decision making
This article was originally published in Scrip
Abbott Laboratories' "voluntary" decision to withdraw the anti-obesity drug Meridia in the US raises more questions as to how the regulatory bodies in the US and the EU deal with products whose benefit-risk profiles are judged wanting.
You may also be interested in...ï»¿
The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage.
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.